Quadruple therapy is cost-effective for HFrEF, according to results published in JACC: Heart Failure. Gregg Fonarow, MD, and colleagues assessed 1,000 simulated patients with HFrEF, comparing quadruple therapy versus triple and double therapy. Quadruple therapy increased life-years by 1.73 and 2.87 compared with triple therapy and double therapy, respectively, and quality-adjusted life-years by 1.12 and 1.85, respectively. Incremental cost-effectiveness ratios of quadruple therapy versus triple and double therapy were $81,000 and $51,081, respectively. “These findings highlight the need for improved access and optimal implementation of comprehensive quadruple therapy,” Dr. Fonarow and colleagues wrote.
